ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,637Medicare Part D Prescriptions Filled, Including Refills

Rank: 206 out of 890

$508K Total Retail Price of All Prescriptions

Rank: 242 out of 890

694 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
42% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 694 patients filled at least one prescription for a schedule two drug, compared to an average of 2%.

Schedule Three
Controlled Substances

13% of this provider’s 694 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

3% of this provider’s 8,170 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

20% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
SIMVASTATIN 495 415 1 5
HYDROCHLOROTHIAZIDE 485 360 2 9
AMLODIPINE BESYLATE 474 360 3 1
OMEPRAZOLE 353 303 4 8
LEVOTHYROXINE SODIUM 312 283 5 2
LISINOPRIL 309 244 6 4
METFORMIN HCL 252 201 7 6
METOPROLOL SUCCINATE 252 178 7 17
FUROSEMIDE 237 183 9 7
PRAVASTATIN SODIUM 195 167 10 10
LISINOPRIL-HYDROCHLOROTHIAZIDE 194 137 11 21
ATORVASTATIN CALCIUM 166 146 12 13
ATENOLOL 156 111 13 23
MELOXICAM 142 113 14 18
LOSARTAN POTASSIUM 141 123 15 29
TRAMADOL HCL 137 102 16 16
ZOLPIDEM TARTRATE 131 65 17 19
GABAPENTIN 123 89 18 12
CLONIDINE HCL 122 70 19 35
HYDROCODONE-ACETAMINOPHEN 122 74 S3 19 3
NEXIUM 117 45 21 14
GLIMEPIRIDE 108 70 22 27
SERTRALINE HCL 106 92 23 26
QUINAPRIL HCL 105 97 24 116
AMOXICILLIN 103 79 25 94
ALLOPURINOL 103 74 25 31
CITALOPRAM HBR 89 66 27 20
WARFARIN SODIUM 89 79 27 24
METOPROLOL TARTRATE 88 70 29 15
CLOPIDOGREL 86 78 30 28
TAMSULOSIN HCL 85 59 31 32
NAMENDA 82 82 32 36
LOSARTAN-HYDROCHLOROTHIAZIDE 79 69 33 57
CRESTOR 75 64 34 25
AZITHROMYCIN 75 61 34 37
FENOFIBRATE 75 68 34 74
PLAVIX 73 63 37 42
PANTOPRAZOLE SODIUM 72 63 38 34
NAPROXEN 70 50 39 84
GLIPIZIDE 67 59 40 62
VERAPAMIL ER 66 49 41 87
POTASSIUM CHLORIDE 65 58 42 11
PROAIR HFA 65 58 42 55
DONEPEZIL HCL 63 55 44 30
CARVEDILOL 61 49 45 22
FLUTICASONE PROPIONATE 61 45 45 39
BYSTOLIC 58 58 47 86
LANTUS SOLOSTAR 56 37 48 102
PAROXETINE HCL 56 36 48 68
DIGOXIN 56 49 48 65
FINASTERIDE 55 46 51 108
RAMIPRIL 54 54 52 80
TRIAMTERENE-HCTZ 51 51 53 61
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 14, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.